CARMIL1 Variant 1: A Potential Drug Target for Cancer (G55604)

Target Name: CARMIL1

NCBI ID: G55604

CARMIL1

CARMIL1 Variant 1: A Potential Drug Target for Cancer

CARMIL1 (Carcinoembryonic antigen-1) is a protein that is expressed in a variety of tissues throughout the body, including the skin, hair, and nervous system. It is also a potent cancer-associated antigen, meaning that it has been found to be highly expressed in a variety of cancer types.

One of theCARMIL1 variants, known as CARMIL1 variant 1, has been identified as a potential drug target in the treatment of various diseases. This variant of CARMIL1 is unique because it has a unique structure that differs from other variants.

CARMIL1 variant 1 is a 22kDa protein that is expressed in various tissues throughout the body, including the skin, hair, liver, and spleen. It is also expressed in the blood vessels and the lymphatic system. CARMIL1 variant 1 is characterized by the presence of a unique epitope that is located at its C-terminus.

This epitope is highly conserved and is located in a region of the protein that is involved in cell adhesion and migration. It is possible that CARMIL1 variant 1 may be a drug target because of its unique structure and the involvement of this region in cellular processes.

One of the potential benefits of targeting CARMIL1 variant 1 with drugs is that it is expected to have a more targeted effect on cancer cells than other variants. This is because the unique epitope of CARMIL1 variant 1 is located in a region that is not expressed in other tissues, which may reduce the potential for unintended effects.

Another potential benefit of targeting CARMIL1 variant 1 with drugs is that it is expected to have a more prolonged effect on cancer cells than other variants. This is because the unique epitope of CARMIL1 variant 1 is located in a region that is involved in cell adhesion and migration, which may allow the protein to continue to function for a longer period of time.

In conclusion, CARMIL1 variant 1 is a unique protein that has been identified as a potential drug target for the treatment of various diseases. Its unique structure and the involvement of this region in cellular processes make it an attractive target for drug development. Further research is needed to determine the full potential of CARMIL1 variant 1 as a drug.

Protein Name: Capping Protein Regulator And Myosin 1 Linker 1

Functions: Cell membrane-cytoskeleton-associated protein that plays a role in the regulation of actin polymerization at the barbed end of actin filaments. Prevents F-actin heterodimeric capping protein (CP) activity at the leading edges of migrating cells, and hence generates uncapped barbed ends and enhances actin polymerization, however, seems unable to nucleate filaments (PubMed:16054028). Plays a role in lamellipodial protrusion formations and cell migration (PubMed:19846667)

The "CARMIL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CARMIL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets